CXCR4-targeted radioligand therapy (RLT) with [177Lu]Lu/[90Y]Y-PentixaTher has recently evolved as a promising therapeutic option for patients with advanced hematological cancers. Here, CXCR4 is linked to hematopoietic and lymphoid cell neoplasm.